Sulfonylurea receptor 1, Kir6.2 · PROTEIN COMPLEX · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-13Sulfonylurea receptor 1, Kir6.2 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 11 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q14654. Start with diabetes mellitus, then reuse UniProt Q14654 as the stable protein anchor across project notes and exports.
Start with diabetes mellitus, then reuse UniProt Q14654 as the stable protein anchor across project notes and exports.
Sulfonylurea receptor 1, Kir6.2 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block. 11 linked drugs remain visible in the same block.
Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include ACETOHEXAMIDE, CHLORPROPAMIDE, GLICLAZIDE, GLIMEPIRIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyATP-sensitive inward rectifier potassium channel 11
Review this target as Sulfonylurea receptor 1, Kir6.2, mapped to UniProt Q14654. ChEMBL maps the protein component as ATP-sensitive inward rectifier potassium channel 11. Sequence length is 390 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Sulfonylurea receptor 1, Kir6.2 as ChEMBL target CHEMBL2096972, mapped to UniProt Q14654. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Sulfonylurea receptor 1, Kir6.2 is the right protein anchor across sources, using UniProt Q14654 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why diabetes mellitus is currently framed as approved-linked support. It currently carries 11 linked drugs in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Sulfonylurea receptor 1, Kir6.2 |
| Target Type | PROTEIN COMPLEX |
| Organism | Homo sapiens |
| UniProt | Q14654 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | ATP-sensitive inward rectifier potassium channel 11 |
| UniProt Accession | Q14654 |
| Component Type | Protein |
| Sequence Length | 390 aa |
ATP-sensitive inward rectifier potassium channel 11
Review this target as Sulfonylurea receptor 1, Kir6.2, mapped to UniProt Q14654. ChEMBL maps the protein component as ATP-sensitive inward rectifier potassium channel 11. Sequence length is 390 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
Sulfonylurea receptor 1, Kir6.2 shows approved-linked disease relevance led by diabetes mellitus. 5 more disease programs remain visible in the same review block.
Start review with diabetes mellitus because it currently carries approved-linked support. Linked drugs include ACETOHEXAMIDE, CHLORPROPAMIDE, GLICLAZIDE, GLIMEPIRIDE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL134168 | 8.52 | IC50 | 3.0 | Preclinical |
| CHEMBL472 | 8.37 | IC50 | 4.3 | Approved |
| CHEMBL354554 | 7.16 | EC50 | 70.0 | Preclinical |
| CHEMBL568795 | 7.1 | EC50 | 80.0 | Preclinical |
| CHEMBL212041 | 7.09 | IC50 | 81.0 | Preclinical |
| CHEMBL5285443 | 7.0 | EC50 | 100.0 | Preclinical |
| CHEMBL133663 | 6.92 | IC50 | 120.0 | Preclinical |
| CHEMBL210749 | 6.8 | EC50 | 160.0 | Preclinical |
| CHEMBL212041 | 6.75 | EC50 | 180.0 | Preclinical |
| CHEMBL135091 | 6.75 | IC50 | 180.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 21 | 48 | 6.0 |
| protein complex format | 2 | 1 | 5.8 |
| assay format | 1 | 0 | — |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| cell-based format | 10 | 11 | 6.0 |
| assay format | 3 | 7 | 5.7 |